MX2018004361A - Nuevos compuestos para el tratamiento de la fibrosis quistica. - Google Patents

Nuevos compuestos para el tratamiento de la fibrosis quistica.

Info

Publication number
MX2018004361A
MX2018004361A MX2018004361A MX2018004361A MX2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A MX 2018004361 A MX2018004361 A MX 2018004361A
Authority
MX
Mexico
Prior art keywords
cystic fibrosis
treatment
novel compounds
cftr
stabilizing
Prior art date
Application number
MX2018004361A
Other languages
English (en)
Inventor
V Patel Sachin
A Gfesser Gregory
John Robert Newsome Gregory
Desroy Nicolas
Akkari Rhalid
Emiel Van Der Plas Steven
D Cowart Marlon
R Kym Philip
Wang Xueqing
Jonathan Alvey Luke
Luc Marie Gosmini Romain
Isabelle Roger Claes Pieter
S Brown Brian
Shrestha Anurupa
Marie Bock Xavier
De Lemos Elsa
Duthion Béranger
Gaëtan Housseman Christopher
Karel Jansen Koen
Ji Jianguo
Mammoliti Oscar
Jeanne Marie Menet Christel
Merayo Merayo Nuria
C Swift Elizabeth
Jules Hector De Wilde Gert
Marie Elise Palisse Adeline
Rafaël Pizzonero Mathieu
Tse Chris
E Conrath Katja
Cyr Douglas
Lefrancois Jean-Michel
Original Assignee
Abbvie Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Sarl filed Critical Abbvie Sarl
Publication of MX2018004361A publication Critical patent/MX2018004361A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un agente corrector capaz de estabilizar una proteína reguladora de la conductancia transmembrana en la fibrosis quística (CFTR) recién sintetizada, útil en el tratamiento de la fibrosis quística.
MX2018004361A 2015-10-09 2016-10-07 Nuevos compuestos para el tratamiento de la fibrosis quistica. MX2018004361A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562239699P 2015-10-09 2015-10-09
PCT/IB2016/056035 WO2017060879A1 (en) 2015-10-09 2016-10-07 Novel compounds for treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
MX2018004361A true MX2018004361A (es) 2018-09-18

Family

ID=57200058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004361A MX2018004361A (es) 2015-10-09 2016-10-07 Nuevos compuestos para el tratamiento de la fibrosis quistica.

Country Status (9)

Country Link
US (1) US10130622B2 (es)
EP (1) EP3359540A1 (es)
JP (1) JP2018529707A (es)
CN (1) CN108602816A (es)
AU (1) AU2016333907A1 (es)
BR (1) BR112018007165A2 (es)
CA (1) CA3000802A1 (es)
MX (1) MX2018004361A (es)
WO (1) WO2017060879A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3191010A1 (en) * 2014-10-31 2016-05-06 AbbVie Global Enterprises Ltd. Substituted chromanes and method of use
JP6779992B2 (ja) * 2015-10-09 2020-11-04 アッヴィ・エス・ア・エール・エル Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法
GB201905711D0 (en) * 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
DK1773816T3 (en) 2004-06-24 2015-01-26 Vertex Pharma Modulators of ATP-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
CA2688004C (en) 2007-05-25 2016-07-05 Vertex Pharmaceuticals Incorporated Thienopyridone compounds for use as modulators of cystic fibrosis transmembrane conductance regulator
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
WO2009076593A1 (en) 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20110074916A (ko) 2008-10-23 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 Ｎ-(4-(7-아자비시클로［2.2.1］헵탄-7-일)-2-(트리플루오로메틸)페닐)-4-옥소-5-(트리플루오로메틸)-1,4-디히드로퀴놀린-3-카르복스아미드의 고체 형태
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
ES2553771T3 (es) 2010-10-08 2015-12-11 Nivalis Therapeutics, Inc. Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
PL2760463T3 (pl) 2011-09-20 2019-05-31 Univ North Carolina Chapel Hill Regulacja kanałów sodowych przez białka PLUNC
EP2922852A4 (en) * 2012-11-20 2016-05-25 Discoverybiomed Inc CFTR SMALL MOLECULE CORRECTIVES
BR112015027964B1 (pt) 2013-05-07 2023-01-10 Galapagos Nv Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística
DK3030568T3 (en) 2013-08-08 2019-01-07 Galapagos Nv THIENO [2,3-C] PYRANES AS CFTR MODULATORS
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
MX2017005663A (es) 2014-10-31 2018-03-01 Abbvie Sarl Tetrahidropiranos sustituidos y metodo de uso.
CA3191010A1 (en) 2014-10-31 2016-05-06 AbbVie Global Enterprises Ltd. Substituted chromanes and method of use

Also Published As

Publication number Publication date
WO2017060879A1 (en) 2017-04-13
BR112018007165A2 (pt) 2019-01-22
CA3000802A1 (en) 2017-04-13
US20170100386A1 (en) 2017-04-13
CN108602816A (zh) 2018-09-28
AU2016333907A1 (en) 2018-04-12
JP2018529707A (ja) 2018-10-11
US10130622B2 (en) 2018-11-20
EP3359540A1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
IL277491A (en) Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
MX2018004361A (es) Nuevos compuestos para el tratamiento de la fibrosis quistica.
ZA201902124B (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2015328174A8 (en) Modulators of cystic fibrosis transmembrane conductance regulator
MX2020005753A (es) Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
MX2021013638A (es) Composiciones farmaceuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quistica.
EP3556858A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2019010155A (es) Arnm de cftr optimizado por codón novedoso.
EP3099784A4 (en) Improved carbon dioxide fixation via bypassing feedback regulation
MX2018003678A (es) Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion.
GB2571607B (en) Ion source
EP3615084A4 (en) MEMBRANE-ACTIVE MOLECULES
EP3368580A4 (en) ALTERNATIVE POST-TREATMENT OF STABILIZATION OF HIGHLY DISORDERED CELLULOSES
EP3254704A4 (en) Hydrogen peroxide solution supply apparatus
EP3634489A4 (en) IMPROVED METHODS FOR GENERATING SMALL MOLECULAR DEGRADERS AND DIMERIZERS
MY174200A (en) Process for reducing the chlorine content of organotetraphosphites
EP3604293A4 (en) METHOD FOR STABILIZING A HIGHLY PURE ETHYLENE CARBON COMPOSITION
EP3448369A4 (en) COMPOUNDS AND COMPOSITIONS FOR TREATING THE METABOLISM SYNDROME AND METHOD THEREFOR
EP3279660A4 (en) Preservative solution for heme protein, and method for stabilizing heme protein
MX2017010899A (es) Proceso para la preparacion de triazoles.
AU2015905412A0 (en) Quality Integral regulator Software Development Project (VENQIR)
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
UA97937U (uk) Матеріал для інтерференційних покриттів